Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-24T13:05:24.422Z Has data issue: false hasContentIssue false

Section 6 - Public–Private Partnerships in Alzheimer’s Disease Drug Development

Published online by Cambridge University Press:  03 March 2022

Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 455 - 464
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schneider, LS, Mangialasche, F, Andreasen, N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275: 251–83.Google Scholar
Petersen, RC, Doody, R, Kurz, A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985–92.CrossRefGoogle ScholarPubMed
Becker, RE, Greig, NH. Alzheimer’s disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 2008; 5: 346–57.CrossRefGoogle ScholarPubMed
Cummings, JL. Integrating ADNI results into Alzheimer’s disease drug development programs. Neurobiol Aging 2010; 31: 1481–92.Google Scholar
Mueller, SG, Weiner, MW, Thal, LJ, et al. The Alzheimer’s Disease Neuroimaging Initiative. Neuroimaging Clin N Am 2005; 15: 869-xii.CrossRefGoogle ScholarPubMed
Weiner, MW, Aisen, PS, Jack, CR, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202–11.e7.CrossRefGoogle Scholar
Weiner, MW, Veitch, DP, Aisen, PS, et al. 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2015; 11: e1–120.Google Scholar
Weiner, MW, Veitch, DP, Aisen, PS, et al. The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement 2017; 13: 561–71.Google Scholar
Lee, S, Bozeman, B. The impact of research collaboration on scientific productivity. Soc Stud Sci 2005; 35: 673–702.Google Scholar
Jones-Davis, DM, Buckholtz, N. The impact of ADNI: what role do public–private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer’ s disease. Alzheimers Dement 2015; 11: 860–4.Google Scholar
Aisen, PS, Petersen, RC, Donohue, MC, et al. Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010; 6: 239–46.Google Scholar
Jack, CR, Bernstein, MA, Borowski, BJ, et al. Update on the MRI core of the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2010; 6: 212–20.CrossRefGoogle Scholar
Kang, J, Korecka, M, Figurski, MJ, et al. The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimers Dement 2015; 11: 772–91.Google Scholar
Saykin, AJ, Shen, L, Yao, X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement 2015; 11: 792–814.Google Scholar
Toga, AW, Crawford, KL. The Alzheimer’s Disease Neuroimaging Initiative Informatics Core: a decade in review. Alzheimers Dement 2015; 11: 832–9.Google Scholar
Carillo, MC, Bain, LJ, Frisoni, GB, Weiner, MW. Worldwide Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2012; 8: 337–42.Google Scholar
Donohue, MC, Gamst, AC, Thomas, RG, et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials 2011; 32: 685–93.CrossRefGoogle ScholarPubMed
Aisen, PS, Andrieu, S, Sampaio, C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011; 76: 280–6.Google Scholar
Aisen, PS, Vellas, B, Hampel, H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov 2013; 12: 324.Google Scholar
Shaw, LM, Vanderstichele, H, Knapik-Czajka, M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Ann Neurol 2009; 65: 403–13.CrossRefGoogle ScholarPubMed
Jack, CR Jr., Lowe, VJ, Weigand, SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009; 132: 1355–65.CrossRefGoogle ScholarPubMed
Veitch, DP, Weiner, MW, Aisen, PS, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2019; 15: 106–52.CrossRefGoogle ScholarPubMed
Petersen, RC, Thomas, RG, Aisen, PS, et al. Randomized controlled trials in mild cognitive impairment: sources of variability. Neurology 2017; 88: 1751–8.CrossRefGoogle ScholarPubMed
Nelson, PT, Alafuzoff, I, Bigio, EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362–8.Google Scholar
Braak, H, Braak, E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271–8.Google Scholar
Wang, J, Logovinsky, V, Hendrix, SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 2016; 87: 993–9.CrossRefGoogle ScholarPubMed
Wolz, R, Schwarz, AJ, Gray, KR, Yu, P, Hill, DL, Alzheimer’s Disease Neuroimaging Initiative. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology 2016; 87: 1235–41.CrossRefGoogle Scholar
Jelic, V, Kivipelto, M, Winblad, B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006; 77: 429–38.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×